Cooperation 业务合作

Amerigen’s growth business development strategy is focused on three key principles: internal product development; collaborative development; and in-licensing/acquisitions of products and technologies.

爱美津制药全球业务发展战略包含三个方面：内部产品开发、合作开发、以及产品与技术和许可和并购。

In the US market, Amerigen is committed in developing generic and complex products with a robust pipeline of more than 30 ANDAs, half of them are high value First-to-File (FTF) opportunities. In the China market, excepting for commercializing Amerigen’s existing portfolio of approved products, Amerigen is bringing selected complex US ANDAs to China, following the recent regulations by CFDA.

在美国市场，爱美津致力于高难度仿制药的开发，目前已经拥有了30多个产品的产品线，其中近一半是高附加值的首报产品（First-to-file Product）。在中国市场，除了销售与合作目前已经获批的产品之外，爱美津顺应目前中国政府的改革，目前正选择性的将美国的高难度仿制药产品引入到中国市场。

As we expand our China pharmaceuticals business, Amerigen is committed to seeking local partnerships that fit our capabilities, enhance our corporate goals and strengthen our competitive position. We regard partnership and collaboration as an integral part of our China business development strategy. This important initiative is supported by a local BD team.

目前我们正在积极开拓中国市场的业务，爱美津希望寻求本土的合作机会，能够符合公司的战略目标、适合公司的核心竞争力并能够提升公司的竞争地位。这类合作是中国业务拓展战略非常重要的一部分，目前由本土的业务拓展团队负责。

Besides US and China market, Amerigen will also evaluate opportunities in other territories if they may provide strategic returns for the company.

除了美国和中国市场，爱美津也会评估其它国家/地域的机会，如果这些机会能够给公司带来战略上的回报。

 

If your firm is interested in working with Suzhou Amerigen, contact us.